Intensification Of Upstream Operations With Dynamic Perfusion

The current industrial standard for producing monoclonal antibodies (mAbs) is fed-batch cultivation. However, continuous processing through perfusion shows significant benefits for biomanufacturing in terms of product quality and yield, which makes it a good candidate for upstream process intensification. Despite these benefits, the perfusion process has not emerged as the new standard in biopharmaceutical upstream processing. This is in part due to its high level of complexity and the potential difficulties linked to running processes aseptically over long periods of time. To overcome the complexity of perfusion processes, a dynamic approach can be adopted. In a dynamic approach, a fixed volumetric media feed rate determines the growth rate and metabolic profile of the cell line over time. This approach reduces the overall complexity of the process by removing the need for cell bleed and the daily perfusion rate adjustment. In this presentation we will look at productivity, media consumption and space time yield for different upstream approaches and demonstrate how dynamic perfusion can address some of the challenges with moving to continuous cell culture operations.